Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BND020
MIFTS: 59

Bone Disease

Categories: Bone diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Disease

About this section

MalaCards integrated aliases for Bone Disease:

Name: Bone Disease 12 15 17
Bone Diseases 54 42 43 15 71
Disorder of Skeletal System 71
Skeletal Disorder 54
Skeletal Disease 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0080001
MeSH 43 D001847
SNOMED-CT 67 76069003
ICD10 32 M89 M89.8 M89.9
UMLS 71 C0005940 C0263661
Sources

Summaries for Bone Disease

About this section
MedlinePlus : 42 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Bone Disease, also known as bone diseases, is related to ischemic bone disease and brittle bone disorder, and has symptoms including back pain, bone pain and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs Acetaminophen and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and breast, and related phenotypes are cellular and growth/size/body region

Disease Ontology : 12 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia : 74 Bone disease refers to the medical conditions which affect the... more...

Sources

Related Diseases for Bone Disease

About this section

Diseases in the Bone Disease family:

Trpv4-Related Bone Disorder

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 805)
# Related Disease Score Top Affiliating Genes
1 ischemic bone disease 34.7 TNFSF11 TNFRSF11B SOST RUNX2 PTH DKK1
2 brittle bone disorder 34.1 TNFSF11 TNFRSF11B SOST RUNX2 PTH FGFR3
3 gorham's disease 34.1 TNFSF11 PTH CALCA
4 paget disease of bone 5, juvenile-onset 34.0 TNFSF11 TNFRSF11B TNFRSF11A CALCA
5 osteopetrosis 34.0 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 CTSK CALCA
6 osteitis fibrosa 33.4 SOST PTH FGF23 CALCA BGLAP B2M
7 paget's disease of bone 33.4 TNFSF11 TNFRSF11B TNFRSF11A SOST PTH DKK1
8 osteonecrosis 33.3 TNFSF11 TNFRSF11B RUNX2 PTH DKK1 BGLAP
9 renal osteodystrophy 33.0 VDR TNFSF11 TNFRSF11B SOST PTH FGF23
10 primary hyperparathyroidism 32.9 VDR TNFSF11 TNFRSF11B SOST PTH FGF23
11 arthropathy 32.9 TNFSF11 TNFRSF11B TNFRSF11A B2M ALPL
12 hypophosphatasia 32.9 RUNX2 PTH FGF23 BGLAP ALPP ALPL
13 chronic kidney disease 32.8 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
14 cherubism 32.7 TNFSF11 FGFR3 CALCA
15 hypophosphatasia, adult 32.4 PTH ALPL
16 osteopetrosis, autosomal dominant 2 32.4 TNFSF11 BGLAP ACP5
17 osteopetrosis, autosomal recessive 2 32.3 TNFSF11 CTSK ACP5
18 cleidocranial dysplasia 32.3 RUNX2 BGLAP ALPP ALPL
19 metachondromatosis 32.3 EXT2 EXT1 CTSK
20 enchondromatosis, multiple, ollier type 32.3 RUNX2 PTH FGFR3 EXT2 EXT1 ACP5
21 hypophosphatasia, childhood 32.3 PTH ALPP ALPL
22 bone development disease 32.2 SOST RUNX2 PTH FGFR3 CTSK BGLAP
23 bone resorption disease 32.2 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
24 hyperparathyroidism 32.1 VDR TNFSF11 TNFRSF11B SOST PTH FGF23
25 osteomalacia 32.1 VDR TNFSF11 SOST PTH FGF23 CALCA
26 myeloma, multiple 32.0 TNFSF11 TNFRSF11B SOST RUNX2 PTH FGFR3
27 mammary paget's disease 32.0 TNFSF11 TNFRSF11B TNFRSF11A PTH CTSK CALCA
28 rickets 31.9 VDR PTH FGF23 CALCA BGLAP ALPP
29 bone remodeling disease 31.9 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
30 kidney disease 31.9 VDR TNFRSF11B PTH FGF23 BGLAP B2M
31 secondary hyperparathyroidism 31.8 VDR TNFRSF11B PTH FGF23 CALCA BGLAP
32 osteoporosis 31.8 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
33 osteomyelitis 31.6 TNFSF11 CTSK CALCA ALPL ACP5
34 hypoparathyroidism 31.5 VDR PTH FGF23 CALCA BGLAP ALPP
35 hyperphosphatemia 31.5 VDR TNFRSF11B RUNX2 PTH FGF23 BGLAP
36 endosteal hyperostosis, autosomal dominant 31.4 TNFSF11 TNFRSF11B SOST CTSK ACP5
37 hypophosphatemia 31.4 VDR PTH FGF23 BGLAP B2M ALPL
38 uremia 31.4 VDR TNFRSF11B PTH B2M
39 hyperthyroidism 31.3 PTH CALCA BGLAP ALPP ACP5
40 fibrous dysplasia 31.3 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 FGF23 CALCA
41 bone cancer 31.2 VDR TNFSF11 TNFRSF11B TNFRSF11A PTH CALCA
42 hyperostosis 31.2 TNFRSF11B SOST FGF23 ALPL
43 osteogenic sarcoma 31.2 VDR TNFSF11 TNFRSF11B RUNX2 PTH DANCR
44 parathyroid adenoma 31.2 VDR PTH CALCA BGLAP ALPP
45 nephrolithiasis 31.1 VDR TNFRSF11B PTH FGF23 BGLAP B2M
46 glucocorticoid-induced osteoporosis 31.1 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
47 arthritis 31.1 TNFSF11 TNFRSF11A PTH CTSK ACP5
48 sclerosteosis 31.1 VDR TNFSF11 TNFRSF11B SOST RUNX2 PTH
49 idiopathic hypercalciuria 31.1 VDR TNFSF11 BGLAP
50 monoclonal gammopathy of uncertain significance 31.1 FGFR3 DKK1 B2M

Graphical network of the top 20 diseases related to Bone Disease:



Diseases related to Bone Disease
Sources

Symptoms & Phenotypes for Bone Disease

About this section

UMLS symptoms related to Bone Disease:


back pain, bone pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Disease:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 ALPL B2M BGLAP CTSK DKK1 EXT1
2 growth/size/body region MP:0005378 10.28 ALPL B2M CTSK DKK1 EXT1 FGF23
3 craniofacial MP:0005382 10.24 ALPL CTSK DKK1 EXT1 FGFR3 PTH
4 hematopoietic system MP:0005397 10.18 ALPL B2M BGLAP CTSK FGF23 FGFR3
5 endocrine/exocrine gland MP:0005379 10.16 ALPL B2M BGLAP CTSK FGF23 PTH
6 immune system MP:0005387 10.15 ALPL B2M BGLAP CTSK FGF23 FGFR3
7 digestive/alimentary MP:0005381 10.13 ALPL B2M CTSK EXT1 FGF23 FGFR3
8 limbs/digits/tail MP:0005371 10.13 ALPL CTSK DKK1 EXT1 FGF23 FGFR3
9 mortality/aging MP:0010768 10.07 ALPL B2M DKK1 EXT1 EXT2 FGF23
10 reproductive system MP:0005389 9.85 ALPL B2M BGLAP CTSK FGF23 FGFR3
11 respiratory system MP:0005388 9.56 ALPL CTSK DKK1 FGF23 FGFR3 RUNX2
12 skeleton MP:0005390 9.5 ALPL BGLAP CTSK DKK1 EXT1 EXT2
Sources

Drugs & Therapeutics for Bone Disease

About this section

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Abatacept Approved Phase 4 332348-12-6 10237
5
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
6
alemtuzumab Approved, Investigational Phase 4 216503-57-0
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Lactulose Approved Phase 4 4618-18-2 11333
9
Tibolone Approved, Investigational Phase 4 5630-53-5
10
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
11
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
12
Gliclazide Approved Phase 4 21187-98-4 3475
13
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
14
Calcium carbonate Approved, Investigational Phase 4 471-34-1
15
Testosterone enanthate Approved Phase 4 315-37-7 9416
16
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
17
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
18
Methyltestosterone Approved Phase 4 58-18-4 6010
19
Methadone Approved Phase 4 76-99-3 4095
20
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
21
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
22
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
23
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
24
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
25
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
26
Desogestrel Approved Phase 4 54024-22-5 40973
27
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
28
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
29
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
30
Mycophenolic acid Approved Phase 4 24280-93-1 446541
31
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
32
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
33
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
34
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
35
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
36
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
37
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
38 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
39
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
40
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
41
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
42
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
44 Tocotrienol Investigational Phase 4 6829-55-6
45
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
46
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
47 Antirheumatic Agents Phase 4
48 Omega 3 Fatty Acid Phase 4
49 Tocopherols Phase 4
50 Tocotrienols Phase 4

Interventional clinical trials:

(show top 50) (show all 765)
# Name Status NCT ID Phase Drugs
1 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
2 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
3 A Prospective Study of the InterFuse T(tm) Unknown status NCT02678130 Phase 4
4 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
5 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
6 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
7 Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation Unknown status NCT01729494 Phase 4 Alemtuzumab;rabbit antithymocyte globulin;Belatacept;Tacrolimus;Mycophenolate mofetil;early cessation of steroids
8 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
9 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4 Zoledronic acid
10 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
11 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
12 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant Completed NCT00657852 Phase 4 Disodium pamidronate;Placebo
13 Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis Completed NCT00164008 Phase 4 zoledronic acid vs pamidronate
14 Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3 Completed NCT00889629 Phase 4 Doxercalciferol;placebo;25-OH Vitamin D3
15 A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. Completed NCT00365131 Phase 4 Cerezyme (imiglucerase for injection)
16 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
17 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
18 A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China Completed NCT00774020 Phase 4 Zoledronic acid
19 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
20 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
21 A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women Completed NCT00160264 Phase 4 Lactulose, Vitamin D, Calcium
22 Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia Completed NCT00129623 Phase 4 Placebo;ibandronate [Bonviva/Boniva]
23 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
24 An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies Completed NCT00740129 Phase 4 Zoledronic Acid
25 A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen. Completed NCT00738257 Phase 4 Pamidronate
26 A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation Completed NCT01534065 Phase 4
27 Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial Completed NCT02214563 Phase 4
28 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
29 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
30 Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Completed NCT00772395 Phase 4 Risedronate;Placebo
31 A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women Completed NCT00431431 Phase 4 tibolone;raloxifen
32 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
33 Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation Completed NCT00668200 Phase 4 Reclast (ZOL446, zoledronic acid)
34 A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients Completed NCT00157690 Phase 4 Alendronate;Placebo
35 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
36 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed NCT00159419 Phase 4 Alendronate;Pamidronate
37 NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide Completed NCT01153425 Phase 4 Teriparatide;Zoledronic Acid
38 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
39 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Completed NCT00504166 Phase 4 alendronate sodium
40 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
41 Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
42 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
43 A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Hypophosphatasia (HPP) in Japan Completed NCT02531867 Phase 4
44 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
45 Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
46 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
47 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
48 A Randomized, Double-blind, Placebo-controlled, Phase IV Trial Evaluating the Palliative Benefit of Either Continuing Pamidronate or Switching to Second-line Zoledronic Acid in Breast Cancer Patients With High-risk Bone Metastases. Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
49 A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
50 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa

Search NIH Clinical Center for Bone Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


deferoxamine mesylate

Cochrane evidence based reviews: bone diseases

Sources

Genetic Tests for Bone Disease

About this section
Sources

Anatomical Context for Bone Disease

About this section

MalaCards organs/tissues related to Bone Disease:

40
Bone, Kidney, Breast, Prostate, Bone Marrow, Liver, Lung
Sources

Publications for Bone Disease

About this section

Articles related to Bone Disease:

(show top 50) (show all 13840)
# Title Authors PMID Year
1
Outcomes of a technique combining diaphyseal impaction grafting and metaphyseal cones for severe bone loss in revision total knee arthroplasty. 42
32475283 2020
2
Can isolated removal of osteophytes achieve correction of varus deformity and gap-balance in computer-assisted total knee arthroplasty? 42
32475289 2020
3
D-PLEX500: a local biodegradable prolonged release doxycycline-formulated bone graft for the treatment for peri-implantitis. A randomized controlled clinical study. 42
32500862 2020
4
[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]. 54 61
20416172 2010
5
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. 61 54
19660583 2010
6
The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. 54 61
19931437 2010
7
Osteopontin: an effector and an effect of tumor metastasis. 54 61
20205680 2010
8
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. 54 61
19915614 2010
9
Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. 61 54
19862816 2010
10
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. 54 61
19782692 2010
11
Bone biology and the role of the RANK ligand pathway. 61 54
20128323 2009
12
Serum levels of total-RANKL in multiple myeloma. 54 61
19951882 2009
13
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. 61 54
19587705 2009
14
RUNX2 mutations in Chinese patients with cleidocranial dysplasia. 54 61
19515746 2009
15
Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. 54 61
19201081 2009
16
The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. 61 54
19371798 2009
17
RANKL inhibition for the management of patients with benign metabolic bone disorders. 54 61
19558335 2009
18
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. 61 54
19344283 2009
19
Role of RANKL in bone diseases. 54 61
19185505 2009
20
Cathepsin K: a therapeutic target for bone diseases. 61 54
19338743 2009
21
RANK, RANKL and osteoprotegerin in bone biology and disease. 54 61
19468919 2009
22
Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. 54 61
19098682 2009
23
Clinical applications of RANK-ligand inhibition. 54 61
19356186 2009
24
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. 61 54
19016581 2009
25
Action of RANKL and OPG for osteoclastogenesis. 54 61
19191757 2009
26
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. 61 54
19449179 2009
27
Targeting Src signaling in metastatic bone disease. 61 54
18942061 2009
28
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. 61 54
19554095 2009
29
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. 61 54
18778854 2009
30
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. 61 54
18991786 2008
31
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 61 54
18951767 2008
32
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. 61 54
18829534 2008
33
Vitamin D receptor ligand therapy in chronic kidney disease. 54 61
18826852 2008
34
Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. 54 61
18829486 2008
35
RANKL inhibition in the treatment of bone metastases. 54 61
18685421 2008
36
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. 54 61
18369625 2008
37
Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D? 61 54
18937749 2008
38
Idiopathic severe elevation of serum alkaline phosphatase following adult renal transplantation: case reports. 61 54
18675129 2008
39
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). 61 54
18587716 2008
40
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. 54 61
18038244 2008
41
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. 61 54
18312448 2008
42
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. 61 54
18057140 2008
43
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. 61 54
18294945 2008
44
A case of lethal hypophosphatasia providing new insights into the perinatal benign form of hypophosphatasia and expression of the ALPL gene. 54 61
17922851 2008
45
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. 54 61
17728092 2008
46
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 54 61
17445976 2008
47
Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. 61 54
18208371 2008
48
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. 61 54
17964729 2008
49
Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. 54 61
18404790 2008
50
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. 54 61
17905588 2008
Sources

Variations for Bone Disease

About this section

ClinVar genetic disease variations for Bone Disease:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CACNA1G NM_018896.5(CACNA1G):c.664_666TTC[1] (p.Phe223del)short repeat Likely pathogenic 183285 rs730882202 17:48649314-48649316 17:50571953-50571955
2 SLC39A13 NM_001128225.3(SLC39A13):c.398C>T (p.Thr133Met)SNV Conflicting interpretations of pathogenicity 196579 rs140574574 11:47433573-47433573 11:47412022-47412022
3 46;XY;t(7;12)(q21.13;q24)dnTranslocation Uncertain significance 267805

Copy number variations for Bone Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 43764 10 49062854 52062367 Duplication skeletal anomalies
Sources

Expression for Bone Disease

About this section
Search GEO for disease gene expression data for Bone Disease.
Sources

Pathways for Bone Disease

About this section

Pathways related to Bone Disease according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
RANK Signaling in Osteoclasts 63
Show member pathways
 12.27 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
2
Osteoclast differentiation 36
11.91 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
3
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.74 RUNX2 PTH BGLAP ALPP
4
Rheumatoid arthritis 36
11.73 TNFSF11 TNFRSF11A PTH CTSK ACP5
5
Parathyroid hormone synthesis, secretion and action 36
11.73 VDR TNFSF11 SOST RUNX2 PTH FGF23
6
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.61 TNFSF11 TNFRSF11B TNFRSF11A
7
Endochondral Ossification 1
11.55 RUNX2 PTH FGFR3 ALPL
8
FGF signaling pathway 1
11.34 RUNX2 FGF23 BGLAP
9
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.31 VDR TNFSF11 RUNX2 PTH BGLAP
10
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.88 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 PTH
11
Osteoclast Signaling 1
10.86 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
12
NOTCH1 regulation of human endothelial cell calcification 1
10.8 FGFR3 ALPL
13
Thiamine metabolism 36
10.74 ALPP ALPL
14
Vitamin D Metabolism 1
10.51 VDR PTH
15
Osteoblast Signaling 1
10.5 TNFSF11 TNFRSF11B PTH FGF23 BGLAP
Sources

GO Terms for Bone Disease

About this section

Cellular components related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNFSF11 TNFRSF11B SOST PTH FGFR3 FGF23
2 extracellular space GO:0005615 9.36 TNFSF11 TNFRSF11B SOST PTH FGF23 DKK1

Biological processes related to Bone Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 TNFRSF11B PTH BGLAP B2M
2 cell-cell signaling GO:0007267 9.87 TNFRSF11A PTH FGFR3 CALCA
3 osteoblast differentiation GO:0001649 9.79 RUNX2 BGLAP ALPL
4 cellular calcium ion homeostasis GO:0006874 9.79 VDR PTH CALCA
5 monocyte chemotaxis GO:0002548 9.69 TNFSF11 TNFRSF11A CALCA
6 mammary gland alveolus development GO:0060749 9.64 TNFSF11 TNFRSF11A
7 heparan sulfate proteoglycan biosynthetic process GO:0015012 9.63 EXT2 EXT1
8 response to inorganic substance GO:0010035 9.62 TNFRSF11B BGLAP
9 negative regulation of bone resorption GO:0045779 9.61 TNFRSF11B CALCA
10 endochondral ossification GO:0001958 9.61 RUNX2 FGFR3 ALPL
11 regulation of osteoclast differentiation GO:0045670 9.6 TNFSF11 BGLAP
12 cellular response to vitamin D GO:0071305 9.59 FGF23 BGLAP
13 vitamin D metabolic process GO:0042359 9.58 VDR FGF23
14 response to magnesium ion GO:0032026 9.58 TNFRSF11B FGF23
15 modulation of age-related behavioral decline GO:0090647 9.56 DKK1 B2M
16 skeletal system development GO:0001501 9.56 VDR TNFRSF11B RUNX2 PTH FGFR3 EXT1
17 cellular response to parathyroid hormone stimulus GO:0071374 9.55 SOST FGF23
18 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.54 EXT2 EXT1
19 phosphate ion homeostasis GO:0055062 9.52 PTH FGF23
20 negative regulation of ossification GO:0030279 9.5 SOST DKK1 CALCA
21 TNFSF11-mediated signaling pathway GO:0071847 9.49 TNFSF11 TNFRSF11A
22 cellular polysaccharide biosynthetic process GO:0033692 9.48 EXT2 EXT1
23 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.46 VDR FGF23
24 bone resorption GO:0045453 9.46 TNFSF11 PTH CTSK ACP5
25 response to vitamin D GO:0033280 9.43 PTH BGLAP ALPL
26 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.4 TNFSF11 TNFRSF11A
27 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.37 TNFSF11 TNFRSF11A
28 ossification GO:0001503 9.23 TNFSF11 TNFRSF11A SOST RUNX2 EXT2 EXT1

Molecular functions related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 9.26 EXT2 EXT1
2 alkaline phosphatase activity GO:0004035 9.16 ALPP ALPL
3 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 8.96 EXT2 EXT1
4 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 8.62 EXT2 EXT1
Sources

Sources for Bone Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....